Business UpdateJun 2, 2026, 05:30 AM
Propanc Biopharma CEO Attends Anti-Aging Science Event; PRP Phase 1b Study On Track
AI Summary
Propanc Biopharma's CEO, James Nathanielsz, attended a keynote address on "Rejuvenation and Health: Science for an Ageing Society" at the University of Granada, featuring renowned scientist Dr. Juan Carlos Izpisúa. Nathanielsz highlighted that Propanc's research into proenzymes for age-related diseases, fibrosis, diabetes, and cancer aligns with this pioneering field. The company also announced that its lead asset, PRP, is on schedule to enter a Phase 1b, First-In-Human study in advanced cancer patients, with ongoing collaborations with the Universities of Granada and Jaén.
Key Highlights
- Propanc Biopharma CEO James Nathanielsz attended a keynote address on "Rejuvenation and Health" at the University of Granada.
- The keynote featured Dr. Juan Carlos Izpisúa, a leading scientist in developmental biology and regenerative medicine.
- Propanc's research focuses on using proenzymes to differentiate target cells for age-related diseases, fibrosis, diabetes, and cancer.
- The company's lead asset, PRP, is on schedule to enter a Phase 1b, First-In-Human study in advanced cancer patients.
- Propanc continues its collaboration with the Universities of Granada and Jaén on cell rejuvenation research.
Price Impact
More from PPCB